A candidate plasma protein classifier to identify Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 549-563

  Zhao, Xuemei ^a   Lejnine, Serguei ^a   Spond, Jeffrey ^a   Zhang, Chunsheng ^a   Ramaraj, T C ^a   Holder, Daniel J ^a   Dai, Hongyue ^a,b,c   Weiner, Russell ^a   Laterza, Omar F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SAGE BIONETWORKS   (United States)

^c M2Gen   (United States)

Author keywords

Alzheimer's disease; aptamers; biomarkers; blood; proteome

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CALGRANULIN B; PLASMA PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CLASSIFIER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; AGED; BLOOD; CLASSIFICATION; FEMALE; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; REPRODUCIBILITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AREA UNDER CURVE; BLOOD PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PRINCIPAL COMPONENT ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TAU PROTEINS;

EID: 84911862239     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141149     Document Type: Article

References (74)

1. Selkoe DJ (2013) Snap Shot: Pathobiology of Alzheimer's disease. Cell 154, 468-468.
2. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
3. Mount C, Downton C (2006) Alzheimer disease: Progress orprofit? Nat Med 12, 780-784.
4. Cummings JL (2009) Defining and labeling diseasemodifyingtreatments for Alzheimer's disease. AlzheimersDement 5, 406-418.
5. Sperling RA, Jack CR Jr, Aisen PS (2011) Testing the righttarget and right drug at the right stage. Sci Transl Med 3, 111-33.
6. Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42, 1097-1105.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under theauspices of Department of Health and Human Services TaskForce on Alzheimer's Disease. Neurology 34, 939-944.
8. Glenner GG, Wong CW, Quaranta V, Eanes ED (1984) Theamyloid deposits in Alzheimer's disease: Their nature andpathogenesis. Appl Pathol 2, 357-369.
9. Lee VM, Trojanowski JQ (1992) The disordered neuronalcytoskeleton in Alzheimer's disease. Curr Opin Neurobiol 2, 653-656.
10. Jack CR Jr, Holtzman DM (2013) Biomarker modeling ofAlzheimer's disease. Neuron 80, 1347-1358.
11. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinalfluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
12. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der FlierWM (2009) CSF biomarker levels in early and late onsetAlzheimer's disease. Neurobiol Aging 30, 1895-1901.
13. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, BlennowK (2009) CSF biomarkers and incipient Alzheimer diseasein patients with mild cognitive impairment. JAMA 302, 385-393.
14. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognosticvalue of CSF markers of Alzheimer's disease pathology inpatients with subjective cognitive impairment or mild cognitiveimpairment in the DESCRIPA study: A prospectivecohort study. Lancet Neurol 8, 619-627.
15. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, TrojanowskiJQ (2009) Cerebrospinal fluid biomarker signaturein Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
16. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM (2011) Comparison of analytical platforms for cerebrospinalfluid measures of beta-amyloid 1-42, total tau, and p-tau181for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68, 1137-1144.
17. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR Jr, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, ThompsonPM (2010) 3D PIB and CSF biomarker associations withhippocampal atrophy in ADNI subjects. Neurobiol Aging 31, 1284-1303.
18. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease withPittsburgh Compound-B. Ann Neurol 55, 306-319.
19. Drzezga A (2010) Amyloid-plaque imaging in early anddifferential diagnosis of dementia. Ann Nucl Med 24, 55-66.
20. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from theAustralian Imaging, Biomarkers and Lifestyle (AIBL) studyof aging. Neurobiol Aging 31, 1275-1283.
21. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment ofAbeta and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
22. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, Perani D, Forsberg A, Langstrom B, Scheinin N, Karrasch M, Nagren K, Grimmer T, Miederer I, Edison P, Okello A, Van Laere K, Nelissen N, Vandenbulcke M, Garibotto V, Almkvist O, Kalbe E, Hinz R, Herholz K (2013) A European multicentre PET study of fibrillar amyloid inAlzheimer's disease. Eur J Nucl Med Mol Imaging 40, 104-114.
23. Mori T, Maeda J, Shimada H, Higuchi M, Shinotoh H, Ueno S, Suhara T (2012) Molecular imaging of dementia. Psychogeriatrics12, 106-114.
24. Hua X, Leow AD, Lee S, Klunder AD, Toga AW, Lepore N, Chou YY, Brun C, Chiang MC, Barysheva M, JackCR Jr, Bernstein MA, Britson PJ, Ward CP, Whitwell JL, Borowski B, Fleisher AS, Fox NC, Boyes RG, Barnes J, Harvey D, Kornak J, Schuff N, Boreta L, Alexander GE, Weiner MW, Thompson PM, Alzheimer's Disease Neuroimaging, Initiative (2008) 3D characterization of brain atrophy inAlzheimer's disease and mild cognitive impairment usingtensor-based morphometry. Neuroimage 41, 19-34.
25. Morra JH, Tu Z, Apostolova LG, Green AE, Avedissian C, Madsen SK, Parikshak N, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM (2008) Validation of a fullyautomated 3D hippocampal segmentation method using subjectswith Alzheimer's disease mild cognitive impairment, andelderly controls. Neuroimage 43, 59-68.
26. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B (2009) Automated MRI measures identifyindividuals with mild cognitive impairment and Alzheimer'sdisease. Brain 132, 2048-2057.
27. Dickerson BC, Wolk DA (2012) MRI cortical thicknessbiomarker predicts AD-like CSF and cognitive decline innormal adults. Neurology 78, 84-90.
28. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, KoeppeRA (2010) The Alzheimer's Disease Neuroimaging Initiative positronemission tomography core. Alzheimers Dement 6, 221-229.
29. Guntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S (2010) Plasma gelsolinis decreased and correlates with rate of decline in Alzheimer'sdisease. J Alzheimers Dis 21, 585-596.
30. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-basedplasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050.
31. Lista S, Faltraco F, Prvulovic D, Hampel H (2013) Blood andplasma-based proteomic biomarker research in Alzheimer'sdisease. Prog Neurobiol 101-102, 1-17.
32. Zurbig P, Jahn H (2012) Use of proteomic methods in theanalysis of human body fluids in Alzheimer research. Electrophoresis33, 3617-3630.
33. Bazenet C, Lovestone S (2012) Plasma biomarkers forAlzheimer's disease: Much needed but tough to find. Biomark Med 6, 441-454.
34. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinicalAlzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
35. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R (2010) A serumprotein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
36. Nagele E, Han M, Demarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer's disease based on disease-specificautoantibody profiles in human sera. PLoS One 6, e23112.
37. Leung R, Proitsi P, Simmons A, Lunnon K, Guntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S (2013) Inflammatory proteins in plasma are associated with severityof Alzheimer's disease. PLoS One 8, e64971.
38. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz-ArrastiaR (2011) Ablood-based algorithm for the detection ofAlzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
39. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN (2012) Blood-based protein biomarkers fordiagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
40. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJ (2014) Candidateblood proteome markers of Alzheimer's disease onset andprogression: A systematic review and replication study. J Alzheimers Dis 38, 515-531.
41. Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Dobson RJ (2014) Alzheimer's disease biomarker discovery using SOMAscanmultiplexed protein technology. Alzheimers Dement, doi:10. 1016/j. jalz. 2013. 09. 016.
42. Reddy MM, Wilson R, Wilson J, Connell S, Gocke A, Hynan L, German D, Kodadek T (2011) Identification of candidateIgG biomarkers for Alzheimer's disease via combinatoriallibrary screening. Cell 144, 132-142.
43. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, Leverenz JB (2013) MicroRNA in Alzheimer's disease:An exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 18, 455-466.
44. Sheinerman KS, Umansky SR (2013) Circulating cell-freemicroRNA as biomarkers for screening, diagnosis and monitoringof neurodegenerative diseases and other neurologicpathologies. Front Cell Neurosci 7, 150.
45. Cheng L, Quek CY, Sun X, Bellingham SA, Hill AF (2013) The detection of microRNA associated with Alzheimer's diseasein biological fluids using next-generation sequencingtechnologies. Front Genet 4, 150.
46. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J, Ruprecht K, Paul F, Stahler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A (2013) A blood based12-miRNA signature of Alzheimer disease patients. Genome Biol 14, R78.
47. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identifyantecedent memory impairment in older adults. Nat Med20, 415-418.
48. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterizationand outcome. Arch Neurol 56, 303-308.
49. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: Earlydetection of dementia: Mild cognitive impairment (anevidence-based review) . Report of the Quality StandardsSubcommittee of the American Academy of Neurology. Neurology56, 1133-1142.
50. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D (2010) Aptamer-based multiplexedproteomic technology for biomarker discovery. PloS One 5, e15004.
51. Kuhn M, Johnson K (2013) Applied Predictive Modeling:A step-by-step guide. Springer Series in Statistics, Edition:2013.
52. Diaz-Uriarte R, Alvarezd A (2006) Gene selection and classificationof microarray data using random forest. BMC Bioinformatics 7, 3.
53. Svetnik V, Liaw A, Tong C, Wang T (2004) Application ofBreiman's random forest to modeling structure-activity relationshipsof pharmaceutical molecules. In Multiple ClassifierSystems: Lecture Notes in Computer Science 3077, Roli F, Kittler J, Windeatt T, eds. pp. 334-343.
54. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M (2011) pROC: An open-source package for Rand S+ to analyze and compare ROC curves. BMC Bioinformatics12, 77.
55. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid beta-relatedbiomarkers in Alzheimer's disease. Neuromolecular Med 14, 65-73.
56. Lampert EJ, Roy CK, Hostage CA, Petrella JR, DoraiswamyPM (2013) Prevalence of Alzheimer's pathologic endophenotypesin asymptomatic and mildly impaired first-degreerelatives. PLoS One 8, e60747.
57. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, HoltzmanDM (2011) Multiplexed immunoassay panel identifiesnovel CSF biomarkers for Alzheimer's disease diagnosis andprognosis. PLoS One 6, e18850.
58. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM (2011) Identification and validation of novelcerebrospinal fluid biomarkers for staging early Alzheimer'sdisease. PLoS One 6, e16032.
59. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, BlankensteinMA (2010) Amyloidbeta (1-42) , total tau, and phosphorylated tau as cerebrospinalfluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248-253.
60. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid betaamyloid42 and tau proteins as biomarkers of Alzheimer-typepathologic changes in the brain. Arch Neurol 66, 382-389.
61. Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G (2006) Cerebrospinal fluid tau and beta-amyloidin Alzheimer patients, disease controls and an age-matchedrandom sample. Neurobiol Aging 27, 1202-1211.
62. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004) Neurochemical diagnosisof Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40ratio and total tau. Neurobiol Aging 25, 273-281.
63. Brody EN, Gold L, Lawn RM, Walker JJ, Zichi D (2010) High-content affinity-based proteomics: Unlocking proteinbiomarker discovery. Expert Rev Mol Diagn 10, 1013-1022.
64. Gold L, Walker JJ, Wilcox SK, Williams S (2012) Advancesin human proteomics at high scale with the SOMAscan proteomicsplatform. N Biotechnol 29, 543-549.
65. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, Pass HI, Rom WN, Siegfried JM, Stewart A, Walker JJ, Weissfeld JL, Williams S, Zichi D, Brody EN (2010) Unlocking biomarker discovery: Large scale applicationof aptamer proteomic technology for early detection oflung cancer. PLoS One 5, e15003.
66. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S (2011) Plasma biomarkers of brainatrophy in Alzheimer's disease. PLoS One 6, e28527.
67. Shepherd CE, Goyette J, Utter V, Rahimi F, Yang Z, Geczy CL, HallidayGM (2006) Inflammatory S100A9 and S100A12proteins in Alzheimer's disease. Neurobiol Aging 27, 1554-1563.
68. Ha TY, Chang KA, Kim J, Kim HS, Kim S, Chong YH, SuhYH (2010) S100a9 knockdown decreases the memory impairmentand the neuropathology in Tg2576 mice, AD animalmodel. PLoS One 5, e8840.
69. Kummer MP, Vogl T, Axt D, Griep A, Vieira-Saecker A, Jessen F, Gelpi E, Roth J, Heneka MT (2012) Mrp14deficiency ameliorates amyloid beta burden by increasingmicroglial phagocytosis and modulation of amyloid precursorprotein processing. J Neurosci 32, 17824-17829.
70. Zhang C, Liu Y, Gilthorpe J, van DM Jr (2012) MRP14(S100A9) protein interacts with Alzheimer beta-amyloid peptideand induces its fibrillization. PLoS One 7, e32953.
71. Lee EO, Yang JH, Chang KA, Suh YH, Chong YH (2013) Amyloid-beta peptide-induced extracellular S100A9 depletionis associated with decrease of antimicrobial peptideactivity in human THP-1 monocytes. J Neuroinflammation10, 68.
72. Kim HJ, Chang KA, Ha TY, Kim J, Ha S, Shin KY, Moon C, Nacken W, Kim HS, Suh YH (2014) S100A9 knockoutdecreases the memory impairment and neuropathologyin crossbreed mice of Tg2576 and S100A9 knockout micemodel. PLoS One 9, e88924.
73. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
74. Mrak RE, Griffin WS (2005) Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8, 369-375.